Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorChumsri, Saranya
dc.contributor.authorLi, Zhuo
dc.contributor.authorSerie, Daniel J.
dc.contributor.authorNorton, Nadine
dc.contributor.authorMashadi-Hossein, Afshin
dc.contributor.authorTenner, Kathleen
dc.contributor.authorSaura Manich, Cristina
dc.date.accessioned2022-09-07T12:08:48Z
dc.date.available2022-09-07T12:08:48Z
dc.date.issued2022-05-24
dc.identifier.citationChumsri S, Li Z, Serie DJ, Norton N, Mashadi-Hossein A, Tenner K, et al. Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials. NPJ Breast Cancer. 2022 May 24;8:68.
dc.identifier.issn1662-453X
dc.identifier.urihttps://hdl.handle.net/11351/8055
dc.descriptionCàncer de mama; Marcadors predictius
dc.description.sponsorshipResearch reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180882 and U24CA196171 (to the Alliance for Clinical Trials in Oncology); UG1CA233180, UG1CA232760, UG1CA233373, and U10CA180821. https://acknowledgments.alliancefound.org. Also supported in part by funds from the Department of Defense W81XWH-18-1-0562 and −0563 and W81XWH-16-1-0265 and 0266, as well as the Breast Cancer Research Foundation (BCRF-19-161), Bankhead-Coley Research Program (6BC05), Susan G. Komen Foundation (SAC190091), and the DONNA Foundation. The content is solely the authors’ responsibility and does not necessarily represent the official views of the National Institutes of Health. Genentech/Roche supplied trastuzumab for both trials. Presented at the Spotlight Session at San Antonio Breast Cancer Symposium 2016 and the ASCO Annual Meeting 2018. Portions of this paper have been published in abstract form: Journal of Clinical Oncology 36, no. 15_suppl (May 20, 2018) 577.
dc.language.isoeng
dc.publisherNature Research
dc.relation.ispartofseriesNPJ Breast Cancer;8
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMama - Càncer - Tractament
dc.subjectExpressió gènica
dc.subjectResposta immunitària
dc.subject.meshBreast Neoplasms
dc.subject.mesh/drug therapy
dc.subject.meshGene Expression Regulation, Neoplastic
dc.subject.meshDose-Response Relationship, Immunologic
dc.titleAdaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1038/s41523-022-00430-0
dc.subject.decsneoplasias de la mama
dc.subject.decs/farmacoterapia
dc.subject.decsregulación de la expresión génica neoplásica
dc.subject.decsrelación dosis-respuesta inmunológica
dc.relation.publishversionhttps://doi.org/10.1038/s41523-022-00430-0
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Chumsri S] Jacoby Center for Breast Health, Mayo Clinic, Jacksonville, FL, USA. [Li Z, Serie DJ] Department of Health and Human Services, Mayo Clinic, Jacksonville, FL, USA. [Norton N] Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA. [Mashadi-Hossein A] NanoString, Inc., Seattle, WA, USA. [Tenner K] Department of Health and Human Services, Mayo Clinic, Rochester, MN, USA. [Saura C] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain
dc.identifier.pmid35610260
dc.identifier.wos000799816800001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple